The emerging therapy of the medication represents a significant advance in the management of diabetes mellitus type 2. Different to existing medications, tirzepatide affects two pathways – glucagon-like peptide-1 (GLP-1) and GIP – leading to improved blood sugar management and anticipated weight loss. Experts are investigating its long-term adv